Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial

Sanofi SA SNY and Regeneron Pharmaceuticals Inc REGN have unveiled detailed results from a Phase 3 trial evaluating Dupixent (dupilumab) in children aged 6 to 11 years for the treatment of asthma.
In a phase 3 trial called Voyage, Dupixent plus standard-of-care asthma therapy significantly cut asthma attacks at Week 24 and improved lung function within two weeks in children ages 6 to 11 with moderate-to-severe asthma, compared with standard care.
Investigators tested the drug in 408 children, dividing them into two groups, each with different markers of type 2 asthma.
The Dupixent patients saw an improvement in asthma control at Week 24 as measured on a 0 to 6 scale of symptom severity and disease impact.
The two groups of Dupixent patients reported score improvements of 1.33 and 1.44 on the scale, respectively, compared with 0.88 and 1.00 for those on placebo.
The improvement for patients on Dupixent more than doubled the "clinically meaningful threshold of 0.5 points," Sanofi said.
There was a significant reduction in mean FeNO levels (airway biomarker), to below the threshold for type 2 inflammation, which is 20 parts per billion (ppb).
Patients taking Dupixent had an average improvement in FeNO levels by -20.59 and -17.84 ppb vs. placebo from baseline to week 12 (p<0.0001 for both values).
Price Action: REGN shares closed 1.5% higher at $523.73, and SNY shares are 1.42% higher at $53.49 during the market session on the last check Monday.